Skip to main content
Premium Trial:

Request an Annual Quote

Elan Pharmaceuticals, Gateway Commons, Alexandria Real Estate Equities, BioMed Realty Trust

Elan Pharmaceuticals Takes 38,000 Square Feet in Second South San Francisco Campus
Elan Pharmaceuticals has signed a lease for 37,981 square feet at Gateway Commons in South San Francisco.
Elan will occupy part of 601 Gateway Blvd., a 12-story, 206,257 square-foot building. The new space is near Gateway Business Park, where Elan occupies four buildings within the six-building, 284,000-square-foot campus (700-1000 Gateway Blvd.).
601 Gateway is one of three buildings that comprise the 201,943-square-foot Gateway Commons, 601-651 Gateway Blvd. The office campus, as well as the adjacent Gateway Business Park, include among their tenants R&D and biotech companies such as Amgen, Anesiva, and Genentech.
Three professionals with NAI BT Burlingame — Gregg Walker, Tom Hayes, and Pat Yaeger — represented Gateway Commons owner Boston Properties. NAI BT Burlingame announced the deal earlier this month.

Alexandria Announces Follow-On Public Offering of2M Shares
Alexandria Real Estate Equities said Sept. 19 it has agreed to sell 2 million shares of common stock in a follow-on public offering, pursuant to a registration statement filed with the US Securities and Exchange Commission. Citi and Merrill Lynch are joint bookrunning managers in connection with the offering, gross proceeds of which will be approximately $200 million.
Alexandria has granted the underwriters a 30-day option to purchase up to 300,000 additional shares to cover over-allotments, if any. The offering is expected to close Tuesday. The company said net proceeds will be used to reduce its outstanding balance on its unsecured line of credit, as well as for general working capital and other purposes, including the selective development, redevelopment, and acquisition of life science properties.
Copies of the prospectus supplement relating to this offering, when available, may be obtained by contacting Citi, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 (telephone: 718-765-6732; fax: 718-765-6734) or Merrill Lynch & Co. (Prospectus Fulfillment), 4 World Financial Center, Prospectus Department, New York, NY 10080.

BioMed Realty Trust Declares Q3 Common Stock and Preferred Stock Dividends
BioMed Realty Trust’s board on Sept. 17 declared a third quarter 2007 dividend of $0.31 per share of common stock. The dividend is equivalent to an annualized dividend of $1.24 per common share.
BioMed also announced that its board of directors has declared a dividend of $0.46094 per share of the company's 7.375 percent Series A Cumulative Redeemable Preferred Stock for the period from July 16 through Oct. 15. The dividends are payable Oct. 15, 2007, to stockholders of record at the close of business on Sept. 28.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.